IA
MYGN icon

Inspire Advisors’s Myriad Genetics MYGN Stock Holding History

Inspire Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,210
Closed -$161K – 714
2025
Q4 		$161K Sell
26,210
-7,073
-21% -$51.3K 0.01% 522
2025
Q3 		$241K Buy
33,283
+11,618
+54% +$69K 0.02% 440
2025
Q2 		$115K Buy
21,665
+8,372
+63% +$49.5K 0.01% 487
2025
Q1 		$118K Buy
13,293
+2,067
+18% +$24.8K 0.01% 436
2024
Q4 		$154K Buy
11,226
+3,644
+48% +$67.2K 0.02% 392
2024
Q3 		$208K Buy
+7,582
New +$205K 0.03% 378

Other funds holding MYGN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Inspire Advisors's MYGN Position: Q1 2026 in Review

Inspire Advisors sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 26,210 shares — an estimated $161K sold.

Inspire Advisors first reported a position in MYGN in Q3 2024 and held it in 6 quarters. The position peaked at $241K in Q3 2025. 203 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Inspire Advisors reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
  • Inspire Advisors sold 26,210 Myriad Genetics shares in Q1 2026, an estimated $161K.
  • Inspire Advisors first reported a position in Myriad Genetics in Q3 2024 and held it in 6 quarters.
  • Inspire Advisors's Myriad Genetics position peaked at $241K in Q3 2025.
  • 203 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Inspire Advisors's 13F filing for Q1 2026, filed 15 May 2026.